
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1040671/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Exenatide and the treatment of patients with Parkinson's disease. Journal of Clinical Investigation, 2013, 123, 2730-2736.	8.2	361
2	Cue-induced striatal dopamine release in Parkinson's disease-associated impulsive-compulsive behaviours. Brain, 2011, 134, 969-978.	7.6	283
3	Motor and Cognitive Advantages Persist 12 Months After Exenatide Exposure in Parkinson's Disease. Journal of Parkinson's Disease, 2014, 4, 337-344.	2.8	206
4	Neurological outcome and quality of life 3Âmonths after COVIDâ€19: A prospective observational cohort study. European Journal of Neurology, 2021, 28, 3348-3359.	3.3	126
5	Apomorphine for Parkinson's Disease: Efficacy and Safety of Current and New Formulations. CNS Drugs, 2019, 33, 905-918.	5.9	92
6	Risk and learning in impulsive and nonimpulsive patients with Parkinson's disease. Movement Disorders, 2010, 25, 2203-2210.	3.9	88
7	Probable RBD and association with neurodegenerative disease markers: A populationâ€based study. Movement Disorders, 2015, 30, 1417-1421.	3.9	86
8	Decision making, impulsivity, and addictions: Do Parkinson's disease patients jump to conclusions?. Movement Disorders, 2012, 27, 1137-1145.	3.9	85
9	Can stress trigger Parkinson's disease?. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 878-881.	1.9	70
10	Novelty seeking behaviour in Parkinson's disease. Neuropsychologia, 2011, 49, 2483-2488.	1.6	66
11	Stroop test performance in impulsive and non impulsive patients with Parkinson's disease. Parkinsonism and Related Disorders, 2011, 17, 212-214.	2.2	65
12	The reorganization of functional architecture in the early-stages of Parkinson's disease. Parkinsonism and Related Disorders, 2018, 50, 61-68.	2.2	64
13	Prevalence and Associated Factors of Sarcopenia and Frailty in Parkinson's Disease: A Cross-Sectional Study. Gerontology, 2019, 65, 216-228.	2.8	63
14	A novel mutation in the VCP gene (G157R) in a german family with inclusionâ€body myopathy with paget disease of bone and frontotemporal dementia. Muscle and Nerve, 2009, 39, 389-391.	2.2	60
15	Neurological outcomes 1Âyear after COVIDâ€19 diagnosis: A prospective longitudinal cohort study. European Journal of Neurology, 2022, 29, 1685-1696.	3.3	57
16	Optimizing odor identification testing as quick and accurate diagnostic tool for Parkinson's disease. Movement Disorders, 2016, 31, 1408-1413.	3.9	55
17	Nonâ€Motor Symptoms in Parkinson's Disease are Reduced by Nabilone. Annals of Neurology, 2020, 88, 712-722.	5.3	55
18	Performance of the Movement Disorders Society criteria for prodromal Parkinson's disease: A populationâ€based 10â€year study. Movement Disorders, 2018, 33, 405-413.	3.9	53

#	Article	IF	CITATIONS
19	Excessive hoarding in Parkinson's disease. Movement Disorders, 2010, 25, 1026-1033.	3.9	50
20	Salivary cortisol levels in Parkinson's disease and its correlation to risk behaviour. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 1107-1111.	1.9	46
21	Clinical aspects of impulsive compulsive behaviours in Parkinson's disease. Journal of the Neurological Sciences, 2011, 310, 183-188.	0.6	42
22	Pathological gambling in Parkinson's disease—a review of the literature. Movement Disorders, 2011, 26, 1976-1984.	3.9	40
23	Uncertainty about mapping future actions into rewards may underlie performance on multiple measures of impulsivity in behavioral addiction: Evidence from Parkinson's disease Behavioral Neuroscience, 2013, 127, 245-255.	1.2	40
24	Dopamine Agonists Rather than Deep Brain Stimulation Cause Reflection Impulsivity in Parkinson's Disease. Journal of Parkinson's Disease, 2013, 3, 139-144.	2.8	39
25	Anxiety and Depression in Parkinson's Disease. Current Treatment Options in Neurology, 2014, 16, 285.	1.8	38
26	Augmentation and impulsive behaviors in restless legs syndrome. Neurology, 2016, 87, 36-40.	1.1	38
27	Impulsiveâ€compulsive spectrum behaviors in pathologically confirmed progressive supranuclear palsy. Movement Disorders, 2010, 25, 638-642.	3.9	33
28	A Retrospective Evaluation of the Frequency of Impulsive Compulsive Behaviors in Parkinson's Disease Patients Treated with Continuous Waking Day Apomorphine Pumps. Movement Disorders Clinical Practice, 2017, 4, 323-328.	1.5	33
29	Is transcranial sonography useful to distinguish scans without evidence of dopaminergic deficit patients from Parkinson's disease?. Movement Disorders, 2012, 27, 1182-1185.	3.9	32
30	Nonmotor <scp>S</scp> ymptoms in <scp>S</scp> ubjects <scp>W</scp> ithout <scp>E</scp> vidence of <scp>D</scp> opaminergic <scp>D</scp> eficits. Movement Disorders, 2015, 30, 976-981.	3.9	32
31	Safety and Tolerability of Active Immunotherapy Targeting α-Synuclein with PD03A in Patients with Early Parkinson's Disease: A Randomized, Placebo-Controlled, Phase 1 Study. Journal of Parkinson's Disease, 2021, 11, 1079-1089.	2.8	29
32	Phenomenology and epidemiology of impulsive-compulsive behaviours in Parkinson's disease, atypical Parkinsonian disorders and non-Parkinsonian populations. Journal of the Neurological Sciences, 2017, 374, 47-52.	0.6	26
33	An autosomal dominant early adult-onset distal muscular dystrophy. Muscle and Nerve, 2000, 23, 1876-1879.	2.2	25
34	Increased reflection impulsivity in patients with ephedroneâ€induced <scp>P</scp> arkinsonism. Addiction, 2013, 108, 771-779.	3.3	25
35	Improvements in rate of development and magnitude of force with intense auditory stimuli in patients with Parkinson's disease. European Journal of Neuroscience, 2011, 34, 124-132.	2.6	24
36	Midbrain hyperechogenicity, hyposmia, mild parkinsonian signs and risk for incident Parkinson's disease over 10 years: A prospective population-based study. Parkinsonism and Related Disorders, 2020, 70, 51-54.	2.2	23

#	Article	IF	CITATIONS
37	Perceptual decision-making in patients with Parkinson's disease. Journal of Psychopharmacology, 2014, 28, 1149-1154.	4.0	22
38	A novelLRRK2 mutation in an Austrian cohort of patients with Parkinson's disease. Movement Disorders, 2007, 22, 1640-1643.	3.9	20
39	Concomitant fragile X-associated tremor ataxia syndrome and Parkinson's disease: a clinicopathological report of two cases: TableÂ1. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 934-936.	1.9	20
40	<i>Banisteriopsis caapi</i> , a Forgotten Potential Therapy for Parkinson's Disease?. Movement Disorders Clinical Practice, 2016, 3, 19-26.	1.5	19
41	Jumping to conclusions in untreated patients with Parkinson's disease. Neuropsychologia, 2016, 85, 19-23.	1.6	19
42	Verbal adynamia in parkinsonian syndromes: behavioral correlates and neuroanatomical substrate. Neurocase, 2018, 24, 204-212.	0.6	19
43	Altruistic punishment in patients with Parkinson's disease with and without impulsive behaviour. Neuropsychologia, 2011, 49, 103-107.	1.6	18
44	Factors associated with impaired quality of life three months after being diagnosed with COVID-19. Quality of Life Research, 2022, 31, 1401-1414.	3.1	18
45	Lower nucleus accumbens α-synuclein load and D3 receptor levels in Parkinson's disease with impulsive compulsive behaviours. Brain, 2019, 142, 3580-3591.	7.6	17
46	Nabilone for non-motor symptoms of Parkinson's disease: a randomized placebo-controlled, double-blind, parallel-group, enriched enrolment randomized withdrawal study (The NMS-Nab Study). Journal of Neural Transmission, 2019, 126, 1061-1072.	2.8	16
47	Rapid eye movement sleep behavior disorder and rapid eye movement sleep without atonia are more frequent in advanced versus early Parkinson's disease. Sleep, 2021, 44, .	1.1	16
48	The Outcome of Dopamine Dysregulation Syndrome in Parkinson's Disease: A Retrospective Postmortem Study. Movement Disorders Clinical Practice, 2018, 5, 519-522.	1.5	14
49	Haste makes waste: Decision making in patients with restless legs syndrome with and without augmentation. PLoS ONE, 2017, 12, e0174793.	2.5	14
50	Saccadic Direction Errors are Associated with Impulsive Compulsive Behaviours in Parkinson's Disease Patients. Journal of Parkinson's Disease, 2019, 9, 625-630.	2.8	13
51	Application of a Simple Parkinson's Disease Risk Score in a Longitudinal <scp>Populationâ€Based</scp> Cohort. Movement Disorders, 2020, 35, 1658-1662.	3.9	11
52	Application of the Updated Movement Disorder Society Criteria for Prodromal Parkinson's Disease to a Populationâ€Based 10‥ear Study. Movement Disorders, 2021, 36, 1464-1466.	3.9	11
53	Reflection impulsivity perceptual decisionâ€making in patients with restless legs syndrome. Annals of Clinical and Translational Neurology, 2018, 5, 315-322.	3.7	10
54	Effects of Nabilone on Sleep Outcomes in Patients with Parkinson's Disease: A Postâ€hoc Analysis of <scp>NMSâ€Nab</scp> Study. Movement Disorders Clinical Practice, 2022, 9, 751-758.	1.5	10

#	Article	IF	CITATIONS
55	In a Rush to Decide: Deep Brain Stimulation and Dopamine Agonist Therapy in Parkinson's Disease. Journal of Parkinson's Disease, 2014, 4, 579-583.	2.8	9
56	Time will tell: Decision making in premanifest and manifest Huntington's disease. Brain and Behavior, 2020, 10, e01843.	2.2	9
57	Effects of Dopamine on Sensitivity to Social Bias in Parkinson's Disease. PLoS ONE, 2012, 7, e32889.	2.5	9
58	Impact of Impulse Control Disorders on Sleep-Wake Regulation in Parkinson's Disease. Parkinson's Disease, 2015, 2015, 1-7.	1.1	8
59	Augmentation in restless legs syndrome: an eye tracking study on emotion processing. Annals of Clinical and Translational Neurology, 2020, 7, 1620-1627.	3.7	8
60	Handwriting in Alzheimer's Disease. Journal of Alzheimer's Disease, 2021, 82, 727-735.	2.6	7
61	Cardiac sympathetic innervation in Parkinson's disease versus multiple system atrophy. Clinical Autonomic Research, 2022, 32, 103-114.	2.5	7
62	Impaired information sampling in mild dementia of Alzheimer's type but not in healthy aging Neuropsychology, 2015, 29, 353-367.	1.3	6
63	Compulsive sexual behaviour in Parkinson's disease is associated with higher doses of levodopa. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1121-1123.	1.9	6
64	Synonymous mutation in adenosine triphosphatase copperâ€ŧransporting beta causes enhanced exon skipping in Wilson disease. Hepatology Communications, 2022, 6, 1611-1619.	4.3	6
65	Clinical Heterogeneity in Cerebral Hemiatrophy Syndromes. Movement Disorders Clinical Practice, 2016, 3, 382-388.	1.5	5
66	Differential Impact of Education on Cognitive Performance in Neurological Patients with Progressive Cognitive Decline. Journal of Alzheimer's Disease, 2021, 80, 1491-1501.	2.6	5
67	The Frontal Assessment Battery in RLS patients with and without augmentation. Sleep Medicine, 2020, 75, 456-458.	1.6	4
68	Decision making and framing effects in multiple sclerosis. European Journal of Neurology, 2021, 28, 1292-1298.	3.3	4
69	Birds of a Feather Flock Together: Disadvantageous Decision Making in Augmented Restless Legs Syndrome Patients with and without Impulse Control Disorders. Brain Sciences, 2021, 11, 383.	2.3	4
70	Eye Tracking in Patients with Parkinson's Disease Treated with Nabilone–Results of a Phase II, Placebo-Controlled, Double-Blind, Parallel-Group Pilot Study. Brain Sciences, 2022, 12, 661.	2.3	4
71	The long-term outcome of impulsive compulsive behaviours in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1288-1289.	1.9	3
72	Neurobehavioral Sequelae of Psychostimulant Abuse. International Review of Neurobiology, 2015, 120, 161-177.	2.0	2

#	Article	IF	CITATIONS
73	Impaired Inhibitory Control of Saccadic Eye Movements in Cervical Dystonia: An Eyeâ€Tracking Study. Movement Disorders, 2021, 36, 1246-1250.	3.9	2
74	Neuropsychiatric Features of Punding and Hobbyism in Parkinson's Disease. Movement Disorders Clinical Practice, 2022, 9, 82-86.	1.5	2
75	Do Parkinson's Disease Patients Have Deficits in Sequential Sampling Tasks?. Movement Disorders Clinical Practice, 2014, 1, 325-328.	1.5	1
76	Augmentation and impulsive behaviors in restless legs syndrome: Coexistence or association?. Neurology, 2016, 87, 2603-2603.	1.1	1
77	Reply to â€~Impulse control disorders are associated with lower ventral striatum dopamine D3 receptor availability in Parkinson's disease: A [11C]-PHNO PET study.'. Parkinsonism and Related Disorders, 2021, 93, 31-32.	2.2	1
78	Factors associated with augmentation in patients with restless legs syndrome. European Journal of Neurology, 2022, 29, 1227-1231.	3.3	1
79	Reply to letter: Nonmotor symptoms in subjects without evidence of dopaminergic deficits. Movement Disorders, 2016, 31, 1588-1589.	3.9	0
80	The prevalence of impulsive compulsive behaviors in patients treated with apomorphine infusion: a retrospective analysis. Arquivos De Neuro-Psiquiatria, 2021, , .	0.8	0
81	Impulse Control Disorders and the Dopamine Dysregulation Syndrome. , 2022, , 224-240.		0
82	Hospital Admissions of Huntington´s Disease patients in a Huntington´s Disease centre between 2011 and 2016: a retrospective analysis. Movement Disorders Clinical Practice, 0, , .	1.5	0